Approval · Notice of Compliance 18764 · 2016
CAPRELSA: Notice of Compliance 18764
Issued December 8, 2016
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 18764
- Date
- December 8, 2016
- Company
- Sanofi Genzyme, A Division Of Sanofi-Aventis Canada IncToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Revision to the artwork on the labels and revisions to the text in the package insert and product monograph regarding packaging
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| CAPRELSA | Not yet assigned | — |
Medicinal ingredients
- VANDETANIB 100 MG per TAB
- VANDETANIB 300 MG per TAB